Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSUMM.L Share News (SUMM)

  • There is currently no data for SUMM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New Travis chairman buys

Fri, 30th Oct 2009 16:31

Robert Walker, the chairman-designate of Travis Perkins, has bought his first shares in the builders' merchant. Walker was appointed to the Travis Perkins board on 30 September 2009 and he is due to take over as chairman from Tim Stevenson in May 2010. Walker has bought a total of 25,000 shares at a total cost of £194,000. Walker is currently chairman of WH Smith and a non-executive director of Tate & Lyle. In the past he was a non-executive director of plumbing products distributor Wolseley. Walker's executive background is in the consumer products sector having spent many decades with Procter & Gamble and PepsiCo. Walker's appointment to the board coincided with a trading statement from Travis Perkins showing turnover 11% lower in the first nine months of 2009. However, the decline in like-for-like sales in the merchanting division slowed in the third quarter. Net debt has reduced from the £527m reported for the end of June 2009. Top Director BuysBP (BP.) Director name: Mr George DavidAmount purchased: 30,000 @ 584.67p Value: £175,401Travis Perkins (TPK) Director name: Mr Robert M WalkerAmount purchased: 12,500 @ 777.60p Value: £97,200Travis Perkins (TPK) Director name: Mr Robert M WalkerAmount purchased: 12,500 @ 775.40p Value: £96,925AstraZeneca (AZN) Director name: Mr Louis SchweitzerAmount purchased: 1,356 @ 2,751.50p Value: £37,310Summit Corporation (SUMM) Director name: Prof Prof Stephen DaviesAmount purchased: 300,000 @ 5.50p Value: £16,500Top Director SellsClarkson (CKN) Director name: Dr R M StopfordAmount sold: 5,000 @ 830.80p Value: £41,540
More News
24 Feb 2016 12:35

Summit Therapeutics hails strong C-difficile findings

(ShareCast News) - Summit Therapeutics has reported that pre-clinical research into its treatment for the Clostridium difficile hospital superbug has found it to be a "novel and potent antibiotic". A peer-reviewed paper has been produced based on a study of Summit's ridinilazole versus current stand

Read more
19 Jan 2016 12:48

Summit Therapeutics gains worldwide patent protection for C-diff drug

(ShareCast News) - Summit Therapeutics has won a key patent protecting its novel antibiotic, ridinilazole, for the treatment of infections caused by the Clostridium difficile hospital superbug. The patent will grant Summit exclusivity in Europe for the use of ridinilazole in the treatment of CDI unt

Read more
19 Jan 2016 12:18

Summit Therapeutics Gets European Patent For Antibiotic Ridinilazole

Read more
22 Dec 2015 12:02

Port Erin Biopharma Continues To Look For Investments, Swings To Loss

Read more
17 Dec 2015 12:28

Summit Therapeutics Third Quarter Loss Widens As Pipeline Progresses

Read more
17 Nov 2015 12:17

Summit Therapeutics Extends Alliance With University Of Oxford

Read more
18 Sep 2015 12:50

Summit Therapeutics To Present Positive SMT19969 Data In San Diego

Read more
10 Sep 2015 11:11

Summit Therapeutics Finishes Enrolment For Phase II SMT19969 Trial

Read more
27 Aug 2015 11:48

Summit Therapeutics First Half Loss Widens As It Develops Pipeline

Read more
17 Aug 2015 12:33

Summit Therapeutics surges on positive clinical trial update

(ShareCast News) - Shares in Summit Therapeutics surged after the company said that its phase 1B clinical trial of SMT C1100 for the treatment of Duchenne muscular dystrophy met its primary objective and will now move on to a Phase 2 trial. The drug discovery and development company said half of the

Read more
14 Jul 2015 07:25

LONDON BRIEFING: Iran Nuclear Agreement Hits Oil Prices

Read more
13 Jul 2015 11:23

Summit Therapeutics Says Preclincal Data Support Its DMD Treatment

Read more
8 Jul 2015 12:04

Summit Therapeutics receives FDA fast-track decision for new antibiotic

Drug discovery and development company Summit Therapeutics has received approval from the US and Food Drug Administration (FDA) for its novel antibiotic. The FDA granted fast-track designation for the SMT19969 antibiotic which treats both duchenne muscular dystrophy and C. difficile infection (CDI).

Read more
8 Jul 2015 11:22

Summit Therapeutics Says CDI Antibiotic Given Fast Track Designation

Read more
7 Jul 2015 11:24

Summit Therapeutics Gets European Patent For Muscle Disease Treatment

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.